SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to a recent FDA filing for ANKTIVA and the strategic securing of the Tokyo-172 BCG strain, moves the community believes effectively derisk the company's path to broader bladder cancer market dominance. While the stock faces volatility from ongoing institutional short positions, retail investors are actively discussing these developments as a potential turning point that could force a significant short squeeze.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Investors are actively debating the trajectory of long-term bonds as rising yields and persistent inflation fears fuel speculation about potential Federal Reserve rate hikes. The community remains deeply divided, with some betting on a continued selloff in TLT while others view the current price levels as a tactical buying opportunity amidst broader market uncertainty.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing intense volatility as investors weigh the impact of surging bond yields and a strengthening dollar against broader inflationary pressures. The community is sharply divided, with some traders actively shorting the metal amid signs of a technical breakdown, while others view the pullback as a long-term buying opportunity driven by persistent industrial demand.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as investor sentiment surges following an earnings report that featured a strong revenue beat and upwardly revised full-year guidance, with the community highlighting the brand's rapid store expansion and traffic growth. While some investors remain skeptical about the stock's high valuation multiples, bullish participants are actively discussing its potential to become the next dominant leader in the fast-casual sector, citing a debt-free balance sheet and strong customer loyalty as key long-term advantages.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is facing a sharp selloff and hitting 52-week lows as the CEO cited concerns over consumers feeling stretched on discretionary spending, alongside broader macroeconomic pressures like inflation. While the community is actively debating the company's resilience and potential as a long-term value play, many are skeptical about the stock's persistent downward momentum and are questioning the timing of a potential reversal.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently the central focus of market conversation as investors brace for the company's upcoming earnings report, which many view as a critical bellwether for the sustainability of the broader AI-driven market rally. The community is deeply divided, with bulls anticipating a blowout quarter that could reignite risk appetite, while bears are expressing concern over high valuations and the potential for a "sell-the-news" reaction regardless of the results.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as the stock hits fresh record highs, driven by strong operational performance and growing institutional confidence. The community is actively debating the potential for a future stock split or special dividend, while simultaneously monitoring the stock's defensive leadership amidst broader market rotation.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is currently trending due to intense volatility driven by news of a major labor strike at Samsung Electronics, which has raised concerns over regional semiconductor output and AI hardware supply chains. The community is actively debating the potential for a deeper market correction in the KOSPI index, with many investors weighing the long-term AI-driven memory demand against the immediate risks of margin calls and forced liquidation.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is trending as it prepares to lead the massive SpaceX IPO, which the community is debating alongside the bank's active involvement in the AI sector and institutional credit markets. Investors are also closely monitoring how the firm's leadership in high-stakes dealmaking and its ongoing strategic pivots are positioning the stock ahead of upcoming quarterly earnings.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors weigh the potential impacts of a new fintech executive order against ongoing macro headwinds, such as elevated interest rate concerns and a difficult yield environment. While the community remains deeply polarized, bulls are pointing to long-term fundamentals and recent institutional buying as a buying opportunity, whereas bears are focused on the stock's poor technical performance and the lack of immediate catalysts to reverse the current downtrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Momentum across psychedelic stocks gained after Trump signed an exec order directing the FDA to accelerate review of psychedelic therapies and committed $50 million towards research.</li><li>The company said it holds standardized, stabilized GMP-compliant ibogaine doses in inventory in a market where access to clinical-grade material remains limited.</li><li>Through its investment in PsyLabs, Psyence has built a vertically integrated platform spanning sourcing in Africa through extraction, purification and pharma production.</li></ul>Shares of Psyence Biomedical (PBM) surged into the spotlight again on Monday after the company underscored its pharma-grade ibogaine inventory advantage just as a new White House order boosted momentum behind psychedelic medicine research.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has logged a three-day winning streak, gaining 182% over the same period.&nbsp;<h2 class="st-heading-2">PBM Targets Global Ibogaine Supply Gap</h2>Psyence Biomedical said on Monday that it currently holds standardized, stabilized and Good Manufacturing Practice (GMP)-compliant ibogaine doses in inventory in a market where access to pharma-grade material remains limited and fragmented.Through its investment in PsyLabs, the company has built an integrated platform spanning sourcing at origin in Africa through extraction, purification and pharmaceutical production.&nbsp;“With limited GMP-grade ibogaine available globally, infrastructure and supply capabilities are the differentiator,” CEO Jody Aufrichtig said. “Our Company is positioned not only to support our own programs, but to enable the broader ecosystem as interest in ibogaine continues to grow.”The company added that its vertically integrated platform can reduce delays tied in supply constraints that have historically slowed progress in ibogaine-based clinical research.<h2 class="st-heading-2">PBM Rides FDA Psychedelic Review Momentum</h2>The supply update comes shortly after U.S. President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to expedite review of psychedelic medicines, including ibogaine, while committing $50 million in funding toward related clinical-research programs.At the Oval Office signing ceremony, Trump said emerging psychedelic therapies could have a “tremendous impact” if supported by clinical evidence, particularly for veterans with serious mental-health conditions.&nbsp;Ibogaine, a compound derived from a Central and West African shrub, remains classified as a Schedule I substance in the U.S. but has attracted growing attention for its potential role in treating post-traumatic stress disorder.The policy move triggered a broad rally across psychedelic-therapy developers. Shares of Enveric Biosciences (ENVB) surged 101%, Compass Pathways (CMPS) jumped 42%, Atai Life Sciences (ATAI) gained 22%, and Definium Therapeutics (DFTX) rose 2% on Monday.<h2 class="st-heading-2">PBM Builds Ibogaine Supply From Africa&nbsp;</h2>Operating near ibogaine’s natural source in Central and West Africa, PsyLabs has secured direct access to raw material with in-region processing to support traceable, reliable, and ethically sourced supply.&nbsp;Earlier this year, Psyence said it produced high-purity ibogaine hydrochloride from ethically sourced iboga bark and exported a GMP-compliant psilocybin product, NPX-5, to Australia for a Phase IIb trial in adjustment disorder among patients receiving palliative cancer care.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About PBM?</h2>On Stocktwits, retail sentiment for PBM was ‘extremely bullish’ amid an eye-watering 82,550% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/pbm_ss_png_36a8236907.webp" alt="pbm ss.png" width="967" height="133"><figcaption>TSLA sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/LowDownDog12/message/650809854">said</a>, “Still holding my 5200 shares at 2.40. Bought believing this company could be the first to get ibogaine to market and still do.”<stembedurl>https://stocktwits.com/LowDownDog12/message/650809854</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/livetotradestox/message/650823742">noted</a> PBM's description of itself as the world’s only licensed pharma-grade ibogaine supplier at source level, and said: "Only sounds like a monopoly. At the very least a moat because of high barriers to entry for competitors."<stembedurl>https://stocktwits.com/livetotradestox/message/650823742</stembedurl>The stock has declined 48% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-founder-bull-case-anktiva-breast-cancer-signal/cZBIIqmRICd">IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal</a>

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock Trips Into Spotlight Again: Rare Ibogaine Supply Edge Gets Boost From Trump’s Psychedelic Push

PBM stock extended its rally to a three-day winning streak, gaining about 182% over the period as investors focused on supply benefits in the ibogaine ecosystem.

Equity

From Concrete to Consciousness: Wall Street Chases QXO $17B Megadeal and Psychedelic Moonshots

The week’s first power hour includes a powerful cross-sector narrative: hard assets meet high-concept science. On one side, a massive consolidation in construction materials signals long-term conviction in infrastructure and development. On the other, a cluster of small- and mid-cap biotech names, many tied to next-generation mental health treatments, are catching momentum simultaneously. $PBM, $QXO, $BLD, $XERI, $TOVX, $POET, $SLNH, $ATAI, $PBM, $CMPS

AtaiBeckley Stock Skyrockets As Psychedelic Rally Extends On Trump FastTrack Order

AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews.read more...

AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Rating

<ul class="summary-bullets"><li>Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares.</li><li>Atai is now preparing for its investigational psychedelic drug BPL-003 to enter a late-stage trial this quarter.</li><li>Further, data from Atai’s mid-stage trial of VLS-01 in treatment-resistant depression is expected in the second half of 2026.</li></ul> Shares of AtaiBeckley Inc. (ATAI) surged 28% on Monday and are on track for their best single-day gain if the rally holds, following analyst price target hikes and growing optimism across the psychedelic drug sector after President Trump signed an executive order to accelerate research in the field.Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, while also committing $50 million to federal research into the psychedelic compound called ibogaine.The move boosted shares of companies including Definium Therapeutics (DFTX), Compass Pathways (CMPS), Enveric BioSciences (ENVB), and Psyence Biomedical (PBM), among others.<h2 class="st-heading-2">Wall Street Boost</h2>Separately, Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. Atai is now preparing for BPL-003 to enter a late-stage trial this quarter. The investigational drug is a fast-acting psychedelic designed for treatment-resistant depression (TRD) and alcohol use disorder.The analyst now expects the company to price BPL-003 at a net annual price of $30,000 at launch, in line with Janssen Pharmaceuticals's Spravato nasal spray already approved for treatment-resistant depression. Further, data from Atai’s mid-stage trial of VLS-01 in TRD is expected in the second half of 2026, the analyst noted.Guggenheim, meanwhile, raised the firm's price target on AtaiBeckley to $16 from $11 and kept a ‘Buy’ rating on the shares on Friday. The firm said that it recently met with Atai management, which reinforced its "conviction" in the BPL-003 program heading into late-stage initiation this quarter, the analyst told investors.According to data from Koyfin, all 14 analysts covering ATAI rate it ‘Buy’ or higher. The 12-month average price target on the stock is $13.83, representing a potential upside of about 166% from current trading levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ATAI stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism about the stocks of psychedelic drug developers including ATAI to “trend up for a while.” “This will be a good ride,” they said.<stembedurl>https://www.stocktwits.com/twiggs462/message/650773904</stembedurl>Another user cheered Atai’s great assets and voiced hopes for further rallies in future.<stembedurl>https://www.stocktwits.com/brunoq14/message/650772195</stembedurl><a href="https://stocktwits.com/symbol/ATAI">ATAI stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/agio-stock-slumps-whats-the-novo-connection/cZBd0tMRIzi">AGIO Stock Slumps 25% – What’s The Novo Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ATAI Stock Soars On Track For Best Day On Trump Psychedelics Push And Wall Street Cheers

Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, spurring a rally among psychedelic drug developer stocks. 

<ul class="summary-bullets"><li>The order calls on the FDA to give priority to select psychedelic treatments that have demonstrated positive results in preliminary research.&nbsp;</li><li>The treatments could qualify for priority review, enabling regulators to assess them faster while upholding safety requirements.</li><li>COMP360, Compass’s psilocybin therapy in late-stage trials, has shown relief within a day, with effects lasting up to six months after one or two doses.&nbsp;</li></ul>Compass Pathways (CMPS) stock gained overnight on Sunday as the company voiced support for the White House’s executive action to speed up research, approval, and availability of psychedelic-based treatments.The company specializes in psilocybin therapies, which stand to benefit from faster regulatory timelines tied to its lead candidate.&nbsp;<h2 class="st-heading-2">Regulatory Changes To Speed Access</h2>President Donald Trump on Saturday signed the order to speed up the development, review, and accessibility of treatments targeting complex psychiatric conditions. The policy outlines a coordinated effort across federal agencies to reduce regulatory delays and expand research opportunities. The order instructs the Food and Drug Administration (FDA) to prioritize certain psychedelic drugs that have already shown promise in early studies.&nbsp;These therapies may receive special review vouchers, allowing regulators to evaluate them more quickly without compromising safety standards. In parallel, the FDA and the Drug Enforcement Administration are tasked with designing pathways that permit eligible patients to access investigational treatments still under review, provided they meet baseline safety criteria.<h2 class="st-heading-2">Compass Lead Candidate Gains Momentum</h2>Compass said it is already engaged in ongoing review discussions with the FDA, positioning it to capitalize on the policy shift as it advances treatment for depression.<blockquote>“Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin,” said CEO Kabir Nath.</blockquote>At the center of this development is COMP360, the company’s synthetic psilocybin therapy currently in late-stage trials. Phase 3 trial findings suggest the treatment may produce rapid improvements, with patients experiencing relief within a day and sustained benefits lasting about six months after just 1 or 2 doses.<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways’ stock</a> was up over 2%&nbsp;as of its last after-hours close. Peers&nbsp;Enveric Biosciences and ATAI Life Sciences were up over 3.5% and 1.1%, respectively.&nbsp;The company’s study includes data from more than 1,000 participants, indicating a generally manageable safety profile with short-lived side effects. Beyond depression, Compass is expanding its focus to PTSD, including collaboration with Veterans Affairs programs to explore treatment options.<h2 class="st-heading-2">What Are Retail Traders Saying?&nbsp;</h2>On Stocktwits, retail sentiment for Compass Pathways remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels,&nbsp;which have surged by 2,000% over the past seven days.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_19_214919_png_16ee490f83.webp" alt="CMPS’s Sentiment Meter and Message Volume as of 21:45 p.m. ET on Apr.19, 2026 | Source: Stocktwits" width="930" height="97"><figcaption>CMPS’s Sentiment Meter and Message Volume as of 21:45 p.m. ET on Apr.19, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user&nbsp;<a href="https://stocktwits.com/Canvasback33/message/650726549">expressed</a> optimism about COMP360 receiving approval and availability.&nbsp;“EO [executive order] was the last hurdle in my mind for this stock. Federal govt has cleared the run way for psychedelic medicine and the FDA is on board. I truly believe this will be approved and is going to market. This is the future of mental health.”<stembedurl>https://stocktwits.com/Canvasback33/message/650726549</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Millionaire11/message/650726940">said</a>:&nbsp;“This is not a sell the news event. This news was not expected. This will skyrocket upon FDA approval anticipation. Once FDA approved, I could see a sell the news event but for now enjoy the gains this week.”<stembedurl>https://stocktwits.com/Millionaire11/message/650726940</stembedurl>CMPS stock has declined over 3% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-china-surge-shows-pricing-power-matters-in-a-supply-crunch-retail-bulls-take-notice/cZJUsxBRIUG">Apple’s China Surge Shows Pricing Power Matters In A Supply Crunch – Retail Bulls Take Notice</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

CMPS Stock Surges As White House Psychedelic Push Prompts FDA Review, Boosts COMP360 Prospects

CMPS Stock - On Saturday, President Trump approved a measure to accelerate the development, evaluation, and availability of therapies for mental health disorders. 

CMPS Stock Jumps Overnight After Trump Order Fast-Tracks Psychedelic Therapies

On Saturday, President Trump approved a measure to accelerate the development, evaluation, and availability of therapies for mental health disorders. 


<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire VANCOUVER, BC, Feb. 27...

New Strong Sell Stocks for Jan. 13

ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

ATAI
AtaiBeckley Inc.

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest ATAI News

ATAIAtaiBeckley Inc.